



## Repair Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

February 3, 2022

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Feb. 3, 2022-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows:

### **Guggenheim Oncology Conference**

Date: Thursday, February 10, 2022

Time: 2:00 p.m. Eastern Time

### **11th Annual SVB Leerink Global Healthcare Conference**

Date: Friday, February 18, 2022

Time: 3:00 p.m. Eastern Time

A live webcast of the Guggenheim Oncology Conference fireside chat will be available starting Thursday, February 10, 2022 at 2:00 p.m. Eastern Time in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcast will be archived on the Company's website for 90 days.

A live webcast of the 11th Annual SVB Leerink Global Healthcare Conference presentation will be available on Friday, February 18, 2022 at 3:00 p.m. Eastern Time in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcast will be archived on the Company's website for 90 days.

### **About Repair Therapeutics, Inc.**

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx<sup>®</sup> platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit [reparerx.com](http://reparerx.com).

SNIPRx<sup>®</sup> is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220203005006/en/): <https://www.businesswire.com/news/home/20220203005006/en/>

### **Repair:**

Steve Forte

Chief Financial Officer

Repair Therapeutics Inc.

[info@reparerx.com](mailto:info@reparerx.com)

### **Investors:**

Kimberly Minarovich

Argot Partners

[reparerx@argotpartners.com](mailto:reparerx@argotpartners.com)

### **Media:**

David Rosen

Argot Partners

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

212-600-1902

Source: Repair Therapeutics Inc.